Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
How It Works 
News - Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
Upturn AI Summary - About
Abcellera Biologics Inc(ABCL)
Top performer 
Advisory History & Simulated Performance *
*as per simulation (see disclosures)- ALL
- 1Y
- 1M
- 1W
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- PASS (Skip)
Stock price based on last close Advisory Performance History (Simulated)
Upturn Advisory & Investor View for ABCL
10/28/2026: ABCL (4-star) is currently NOT-A-BUY. Pass it for now.
AbCellera Biologics is a biotechnology company that provides an AI-driven platform for identifying and developing antibody-based therapeutics. Its business model focuses on capturing long-term royalties through partnerships, while simultaneously building an internal drug pipeline to diversify its revenue. Strengths include a highly specialized technology stack that has historically proven its capability in high-pressure discovery scenarios. Investors must monitor risks related to clinical trial outcomes, partner execution, and intense competition in the AI-biotech space. This stock is primarily suited for long-term growth investors who have a high tolerance for the volatility inherent in biotechnology and drug discovery investments.
How to Read the Upturn Advisory
The Upturn Star Rating and the current BUY, SELL, or PASS advisory are generated by Upturn’s AI advisory engine based on proprietary signal analysis, price behavior, advisory history, and historical signal performance.
Company fundamentals, valuation, risks, and news provide supporting context about the business.
Investor Fit
| Investor style | Fit | Why |
|---|---|---|
| Growth investor | Strong fit | The company offers long-term growth potential linked to the success of its AI-driven platform and partner pipelines. |
| Momentum investor | Mixed fit | Momentum is highly conditional on news flow regarding clinical trial results and new partnership announcements. |
| Value investor | Weak fit | The company is in an early-to-growth stage with earnings volatility, making traditional value metrics less applicable. |
| Dividend investor | Weak fit | AbCellera does not pay dividends, prioritizing capital reinvestment for growth. |
| Low-risk investor | Weak fit | High inherent risks in biotechnology discovery and stock price volatility make this unsuitable for low-risk portfolios. |
Risk Profile
| Risk factor | Level | Why it matters |
|---|---|---|
| Price volatility | High | The stock is susceptible to significant swings based on clinical trial outcomes. |
| Valuation risk | Medium / high | Future growth expectations are baked into the valuation, creating risk if milestones are missed. |
| Competition risk (AI competition) | High | The rapid advancement of AI in drug discovery creates constant pressure from new and established players. |
| Business quality | Medium | The business model is strong, but heavily dependent on the success of third-party pharmaceutical partners. |
| Dividend income | Low / none | Investors should not expect income as the company is focused on growth. |
| Execution risk | Medium / high | Translating discovery platform potential into successful commercialized drugs is complex and difficult. |
Price Behavior
Hockey-Stick Growth
The stock demonstrates a Hockey-Stick Growth price path pattern.
Extreme Price Shocks
The stock has experienced exceptionally large and disruptive price movements during the period.
Analysis of Past Performance
Type Stock | Historic Profit 119.19% | Avg. Invested days 36 | Today’s Advisory PASS |
Upturn Advisory Rating  | Upturn Advisory Performance  4.0 | Stock Returns Performance  5.0 |
| Profits based on simulation | Last Close 10/28/2026 |
Upturn Scorecard
Upturn Star Rating 
Company Fundamentals
Financial Health Rating
Growth Momentum Score
Ownership
Top 5 Institutional Investors
Unit Economics (Per $1K Revenue)
Economic Dimensions
Quantitative Style Profile
Style Classification
Quality Focused
Key Highlights
Company Size Mid-Cap Stock | Market Capitalization 4.16B USD | Price to earnings Ratio - | 1Y Target Price 16.82 |
Price to earnings Ratio - | 1Y Target Price 16.82 | ||
Volume (30-day avg) 5.0M shares | Beta 1.41 | 52 Weeks Range 2.75 - 15.02 | Updated Date 10/28/2026 |
52 Weeks Range 2.75 - 15.02 | Updated Date 10/28/2026 | ||
Dividends yield (FY) - | Basic EPS (TTM) -0.54 |
How Company Makes Money
| Business area | What it includes | Retail investor read |
|---|---|---|
| Discovery Partnerships | Research fees, milestone payments, and future royalties from partners. | Revenue is earned when the company helps partners find effective drug candidates. |
| Internal Pipeline | Ownership of internal therapeutic candidates. | Potential for future upside if internal drug candidates succeed in clinical trials. |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Revenue by Geography
Geography revenue - Year on Year
Valuation
Trailing PE - | Forward PE 27.55 | Enterprise Value 3.76B | Price to Sales(TTM) 62.83 |
Enterprise Value 3.76B | Price to Sales(TTM) 62.83 | ||
Enterprise Value to Revenue 53 | Enterprise Value to EBITDA 5.3 | Shares Outstanding 324.05M | Shares Floating 209.04M |
Shares Outstanding 324.05M | Shares Floating 209.04M | ||
Percent Insiders 21.74 | Percent Institutions 36.6 |
Financial Metrics
🧭 Investment Snapshot
Total Revenue (Scale)
Total money earned from selling products or services before any costs. It is needed to understand the scale of the business and its ability to generate income.
Net Income (Profit)
Final profit after all expenses, interest, and taxes are deducted. It is needed to determine the overall profitability available to shareholders.
Free Cash Flow (Cash Strength)
Cash remaining after operating activities and capital expenditures, showing cash available for growth. It is needed to evaluate the company’s ability to invest, pay dividends, or reduce debt.
📈 Growth & Strength
Operating Income (Core Profit)
Profit from core operations after deducting all operating expenses. It is needed to measure how efficiently the company runs its primary business activities.
EBITDA (Cash Earnings)
Earnings before interest, taxes, depreciation, and amortization, indicating operating cash potential. It is needed to compare operating performance across companies without accounting or financing differences.
Gross Profit (Unit Profitability)
Revenue minus cost of revenue, showing profit after direct production costs. It is needed to evaluate core business profitability before overhead expenses.
🛡️ Financial Safety
Cash (Liquidity Buffer)
Total cash and cash equivalents on hand. It is needed to evaluate immediate liquidity and financial flexibility.
Total Debt (Leverage Risk)
Total debt including both short-term and long-term components. It is needed to assess the company’s leverage and financial risk.
Net Working Capital (Short-Term Health)
Current assets minus current liabilities, indicating short-term liquidity strength. It is needed to assess whether the company can meet its short-term obligations.
🧱 Balance Sheet Strength
Stockholder Equity (Net Worth)
Total equity value held by shareholders. It is needed to understand the net worth of the company from the owners’ perspective.
Total Assets (Asset Base)
The full value of everything the company owns, including cash, inventory, equipment, and investments. It is needed to understand the resource base used to generate revenue.
Income Before Tax (Pre-Tax Earnings)
Income before provision for income taxes. It is needed to analyze profitability independent of tax structures.
⚙️ Cost & Drag Factors
Cost of Revenue (Production Cost)
Direct costs required to produce and deliver the products or services sold. It is needed to assess efficiency in production and service delivery.
Total Operating Expenses (Operating Cost)
Indirect costs of running the business such as salaries, marketing, and administration. It is needed to understand how much it costs to sustain ongoing business operations.
Income Tax Expense (Tax Drag)
Amount of taxes paid or payable to the government. It is needed to evaluate the impact of taxation on overall profitability.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.
All company names, trademarks, logos, and brands are the property of their respective owners and are used for identification and informational purposes only. Use of these names, trademarks, and logos does not imply endorsement by their respective owners.